Longboard Pharmaceuticals (LBPH) 10-Q 2023 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Longboard Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 2, 2023	By:	/s/ Kevin R. Lind
		Kevin R. Lind
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: November 2, 2023	By:	/s/ Brandi L. Roberts
		Brandi L. Roberts
		Executive Vice President and Chief Financial Officer
		(Principal Financial and Accounting Officer)